AT355843T

N-biphenylcarbonyl- and n-phenylpyridylcarbonyl substituted bi- and tricyclic azepines and diazepines as vasopressing agonists

Abstract

Type (I) or (II) compounds or its can medicinal salt or Qian drug forms: which y is selected since NR or-(CH2) n of part; which r is hydrogen or (C1-C6) low-level alkyl, and n is 1; (Z) representative (1) benzene ring, by in benzene ring can any selected is a or two a independent to selected since following of replaced base replaced: hydrogen, and (C1-C6) low-level alkyl, and halogen, and cyanide base, and CF3, and hydroxy, and (C1-C6) low-level n-oxygen base, and (C1-C6) low-level n-oxygen base Carbonyl, and carboxy, and -CONH2, and-CONH[(C1-C6) low-level alkyl], and-CON[(C1-C6) low-level alkyl]2; or (2) has a nitrogen Atomic of 6-Yuan Fang family (not saturated) hybrid ring, by in hybrid ring can any selected is (C1-C6) low-level alkyl, and halogen or (C1-C6) low-level n-oxygen base replaced; (w) representative (1) benzene ring, by in benzene ring can any selected is a or two a independent to selected since following of replaced base replaced: hydrogen, and (C1-C6) low-level alkyl, and halogen, and cyanide base, and CF3, and hydroxy, and (C1-C6) low-level n-oxygen base, and or (C1-C6) low-level n-oxygen base Carbonyl, and carboxy, and-CONH2, and-CONH[(C1-C6) low-level alkyl], and-CON[(C1-C6) low-level alkyl]2; or (2) has a nitrogen Atomic of 5-Yuan Fang family (not saturated) hybrid ring, by in hybrid ring can any selected is (C1-C6) low-level alkyl, and (C1-C6) low-level n-oxygen base or halogen replaced; or (3) has a nitrogen Atomic of 6-Yuan Fang family ( Not saturated) hybrid ring, by in hybrid ring can any selected is (C1-C6) low-level alkyl, and halogen or (C1-C6) low-level n-oxygen base replaced; (x) representative has a sulfur Atomic of 5-Yuan Fang family (not saturated) hybrid ring, by in hybrid ring can any selected is (C1-C6) low-level alkyl, and halogen or (C1-C6) low-level n-oxygen base replaced; R1 is type (o or n) by shows part, and R2, and R3, and R7, and R8 and R9 independent to selected since hydrogen, and (C1-C3) low-level alkyl, and OCH3, and halogen, and CF3,-SCH3, OCF3, SCF3, or CN.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

20 members in 12 offices

This recordMember, by publication datePriority claim2 more offices are in the list below

Priority claims1

Priority claims
DocumentOfficeKindDate
28326301United States of AmericaP

Members20

Family members, oldest first
DocumentOfficeKind
CA2444455A1CanadaA1
WO02083145A1World Intellectual Property Organization (WIPO)A1
US2003018024A1United States of AmericaA1
EP1381370A1European Patent Office (EPO)A1
MXPA03009158AMexicoA
BR0208823ABrazilA
CN1516589AChinaA
JP2004530668AJapanA
US2005075328A1United States of AmericaA1
US6903091B2United States of AmericaB2
US2006276456A1United States of AmericaA1
EP1381370B1European Patent Office (EPO)B1
AT355843TThis recordAustriaT
DE60218646D1GermanyD1
DK1381370T3DenmarkT3
US7223752B2United States of AmericaB2
ES2282423T3SpainT3
DE60218646T2GermanyT2
US7465722B2United States of AmericaB2
US2009227565A1United States of AmericaA1